Skip to main navigation
Skip to search
Skip to main content
Icahn School of Medicine at Mount Sinai Home
Help & FAQ
Link opens in a new tab
Search content at Icahn School of Medicine at Mount Sinai
Home
Profiles
Research units
Publications & Research Outputs
Press/Media
Differences in drug-eluting stents used in coronary artery disease
Andreas Synetos
, Konstantinos Toutouzas
, Antonis Karanasos
, Konstantinos Stathogiannis
, Georgia Triantafyllou
, Eleutherios Tsiamis
,
Stamatios Lerakis
, Christodoulos Stefanadis
Research output
:
Contribution to journal
›
Review article
›
peer-review
2
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Differences in drug-eluting stents used in coronary artery disease'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Pharmacology, Toxicology and Pharmaceutical Science
Coronary Artery Disease
100%
Biological Marker
100%
Rapamycin
100%
Everolimus
100%
Paclitaxel
100%
Restenosis
100%
Zotarolimus
100%
Keyphrases
Coronary Artery Disease
100%
Drug-eluting Stent
100%
Stent
33%
Drug Efficacy
16%
Percutaneous Coronary Intervention
16%
Sirolimus
16%
Improved Efficacy
16%
Biological Markers
16%
Paclitaxel
16%
Restenosis
16%
Increased Safety
16%
Zotarolimus-eluting Stent
16%
Clinical Markers
16%
Stent Platforms
16%
Everolimus
16%
Neointimal Proliferation
16%
Plethora
16%
Biological Differences
16%
Late Loss
16%
Class Effect
16%
Polymer Coating
16%
Nursing and Health Professions
Coronary Artery Disease
100%
Drug Eluting Stent
100%
Efficacy
83%
Stent
66%
Everolimus
16%
Percutaneous Coronary Intervention
16%
Biological Marker
16%
Paclitaxel
16%
Restenosis
16%
Rapamycin
16%
Zotarolimus
16%
Medicine and Dentistry
Coronary Artery Disease
100%
Drug-Eluting Stent
100%
Percutaneous Coronary Intervention
16%
Rapamycin
16%
Biological Marker
16%
Everolimus
16%
Paclitaxel
16%
Restenosis
16%
Zotarolimus
16%